3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
10
Unknown
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
17
Precursor Cell Lymphoblastic Leukemia-Lymphoma
6
Gastrointestinal Stromal Tumors
6
Leukemia, Myeloid, Chronic-Phase
4
Leukemia
4
Neoplasms
2
Neoplasm Metastasis
2
Melanoma
2
Sarcoma
1
Relapsed Pediatric Solid Tumor
1
Mesothelioma
1
Meningioma
1
Leukemia, Myeloid
1
Head and Neck Neoplasms
1
Gastrointestinal Neoplasms
1
GIST
1
Drug-Related Side Effects and Adverse Reactions
1
Chordoma
1
Central Nervous System Neoplasms
1
Carcinoma, Adenoid Cystic
1
Brain Neoplasms
1
Interventions
Doxorubicin
19
Radiotherapy
10
Ifosfamide
10
apatinib
9
anlotinib
8
Cyclophosphamide
8
camrelizumab
7
Vincristine
5
Dactinomycin
5
toripalimab
3
Trabectedin
3
Radiation Dose Hypofractionation
3
Ipilimumab
3
Gemcitabine
3
Etoposide
3
Docetaxel
3
selinexor
2
ribociclib
2
envafolimab
2
brostallicin
2
Topotecan
2
Thalidomide
2
Temozolomide
2
Sorafenib
2
Oncolytic Virotherapy
2
Nivolumab
2
Neoadjuvant Therapy
2
Melphalan
2
Magnetic Resonance Spectroscopy
2
Irinotecan
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Sarcoma
×
Imatinib Mesylate
×
Clear all
NCT04138381
2023-03-27
SeliGIST
Grupo Espanol de Investigacion en Sarcomas
Phase 1/2
Unknown
30 enrolled